Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms.
Lymph node metastasis
Pancreatic neuroendocrine neoplasms
Risk factor
Tumor size
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 Jun 2022
24 Jun 2022
Historique:
received:
10
04
2021
revised:
24
10
2021
accepted:
21
05
2022
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
ppublish
Résumé
Although PNENs generally have a better prognosis than pancreatic cancers, some PNENs display malignant behavior including lymph node (LN) metastasis. Complete tumor resection can be the only potentially curative treatment for patients with resectable PNENs. However, the indications for LN dissection are still controversial. Over the last decade, minimally invasive surgery such as laparoscopic pancreatic surgery (LPS) has been increasingly performed for pancreatic tumors including PNENs. To investigate the risk factors for LN metastasis in PNENs and to select appropriate patients for limited surgery by LPS. From April 2001 to December 2019, 92 patients underwent pancreatic resection for PNENs at Kumamoto University Hospital. Finally, 82 patients were enrolled in this study. Using perioperative factors, we examined the predictive factors for LN metastasis in PNENs. Among the 82 patients, the percentage of LN metastasis according to the pathological findings was 12% (10/82 cases). The median tumor size was 12 mm (range: 5-90 mm). The median tumor size in the LN-positive group (37 mm) was significantly larger than that in the LN-negative group (12 mm) ( Larger tumor size (≥ 20 mm) is an independent risk factor for LN metastasis in PNENs. In smaller PNENs (≤ 10 mm), we may be able to choose limited surgery without LN dissection.
Sections du résumé
BACKGROUND
BACKGROUND
Although PNENs generally have a better prognosis than pancreatic cancers, some PNENs display malignant behavior including lymph node (LN) metastasis. Complete tumor resection can be the only potentially curative treatment for patients with resectable PNENs. However, the indications for LN dissection are still controversial. Over the last decade, minimally invasive surgery such as laparoscopic pancreatic surgery (LPS) has been increasingly performed for pancreatic tumors including PNENs.
AIM
OBJECTIVE
To investigate the risk factors for LN metastasis in PNENs and to select appropriate patients for limited surgery by LPS.
METHODS
METHODS
From April 2001 to December 2019, 92 patients underwent pancreatic resection for PNENs at Kumamoto University Hospital. Finally, 82 patients were enrolled in this study. Using perioperative factors, we examined the predictive factors for LN metastasis in PNENs.
RESULTS
RESULTS
Among the 82 patients, the percentage of LN metastasis according to the pathological findings was 12% (10/82 cases). The median tumor size was 12 mm (range: 5-90 mm). The median tumor size in the LN-positive group (37 mm) was significantly larger than that in the LN-negative group (12 mm) (
CONCLUSION
CONCLUSIONS
Larger tumor size (≥ 20 mm) is an independent risk factor for LN metastasis in PNENs. In smaller PNENs (≤ 10 mm), we may be able to choose limited surgery without LN dissection.
Identifiants
pubmed: 35949434
doi: 10.5306/wjco.v13.i6.520
pmc: PMC9244965
doi:
Types de publication
Journal Article
Langues
eng
Pagination
520-528Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors have no conflicts of interest in association with this study. No financial support was received for the work described in this manuscript.
Références
J Hepatobiliary Pancreat Surg. 2009;16(5):639-47
pubmed: 19365596
JAMA Surg. 2013 Oct;148(10):932-9
pubmed: 23986355
Gland Surg. 2018 Feb;7(1):12-19
pubmed: 29629315
Br J Surg. 2012 Jan;99(1):88-94
pubmed: 22135173
Surg Endosc. 2011 May;25(5):1642-51
pubmed: 21184115
BMC Surg. 2015 Apr 25;15:49
pubmed: 25928025
Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70
pubmed: 16924083
HPB (Oxford). 2009 Aug;11(5):422-8
pubmed: 19768147
Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3
pubmed: 17122609
Ann Surg Oncol. 2013 Sep;20(9):2815-21
pubmed: 23771245
Surg Today. 2017 Sep;47(9):1104-1110
pubmed: 28229300
J Gastroenterol. 2012 Jun;47(6):678-85
pubmed: 22350698
J Gastrointest Surg. 2010 Oct;14(10):1536-46
pubmed: 20824378
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
J Surg Oncol. 2016 Sep;114(4):440-5
pubmed: 27334541
J Hepatobiliary Pancreat Sci. 2013 Apr;20(4):421-8
pubmed: 23224732
Ann Surg. 2014 Feb;259(2):197-203
pubmed: 24253141
Br J Surg. 2012 Nov;99(11):1562-8
pubmed: 23027073
JOP. 2010 Mar 05;11(2):135-8
pubmed: 20208321
HPB (Oxford). 2014 May;16(5):397-406
pubmed: 24245906
J Laparoendosc Adv Surg Tech A. 2010 Jun;20(5):435-40
pubmed: 20518689
Chin Med J (Engl). 2015 Dec 20;128(24):3335-44
pubmed: 26668149
Br J Surg. 2014 Oct;101(11):1405-12
pubmed: 25132004
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25
pubmed: 24142395
Ann Surg. 1996 Mar;223(3):280-5
pubmed: 8604908
Ann Oncol. 2008 Oct;19(10):1727-33
pubmed: 18515795
World J Surg. 2004 Dec;28(12):1239-47
pubmed: 15517485
J Gastrointest Surg. 2010 Nov;14(11):1804-12
pubmed: 20589446
Pancreas. 2012 Aug;41(6):840-4
pubmed: 22781907
Am J Surg. 2014 Nov;208(5):775-780
pubmed: 24997491
J Gastrointest Surg. 2016 Dec;20(12):1966-1974
pubmed: 27714644
Eur J Cancer. 2012 Jul;48(11):1608-15
pubmed: 22129889
Ann Surg Oncol. 2014 Oct;21(11):3515-21
pubmed: 24841347
J Am Coll Surg. 2012 Dec;215(6):810-9
pubmed: 22999327
Pancreas. 2014 May;43(4):526-31
pubmed: 24658317
Ann Surg Oncol. 2014 Sep;21(9):2882-8
pubmed: 24740828
Surg Endosc. 2012 Apr;26(4):904-13
pubmed: 22083328
Medicine (Baltimore). 2015 Sep;94(36):e1404
pubmed: 26356692
Surgery. 1996 Dec;120(6):1051-4
pubmed: 8957494
Eur J Surg Oncol. 2014 Nov;40(11):1564-71
pubmed: 25086992
Ann Surg. 2012 Jun;255(6):1048-59
pubmed: 22511003